Leukemia Steering Committee
The NCI Leukemia Steering Committee (LKSC) was established in 2009.
The LKSC follows an efficient, cost-effective, science-driven, and transparent process to identify and promote the "Best Science" in clinical research on leukemia and related diseases by addressing the design and prioritization of phase 3 trials and large phase 2 studies.
Clinical Trials Planning Meetings (CTPMs)
- MDR – 2012
- Acute Lymphocytic Leukemia (ALL) – November 2011
- Chronic Lymphocytic Leukemia (CLL) Working Group – November 2010
- Acute Myelogenous Leukemia (AML) Working Group – October 2010
The following are clinical trials that were approved at the concept stage by the Steering Committee:
|Trial ID||NCT ID||Trial Title|
|CALGB-11002||NCT01420926||A Randomized Phase II Trial of Decitabine-based Induction Strategies for Patients ≥ 60 Years Old with Acute Myeloid Leukemia|
|SWOG-1117||NCT01522976||A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacititdine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)|
|SWOG-1203||NCT01802333||A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or Without Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)|
|ALLIANCE-A041202||NCT01886872||A Randomized Phase III Study of Chlorambucil Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>65 years of age) with Chronic Lymphocytic Leukemia (CLL)|
|ECOG-ACRIN-E1910||NCT02003222||A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Acute Lymphoblastic Leukemia in Adults|
|ECOG-ACRIN-E1912||NCT02048813||A Randomized Phase II/III Study of (PCI-32765) Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)|
CCCT Contact: Lawrence Baizer, Ph.D.